enzalutamide + bicalutamide

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostatic Neoplasms

Conditions

Prostatic Neoplasms

Trial Timeline

Mar 22, 2011 → Nov 8, 2017

About enzalutamide + bicalutamide

enzalutamide + bicalutamide is a phase 2 stage product being developed by Astellas Pharma for Prostatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01288911. Target conditions include Prostatic Neoplasms.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT01664923Phase 2Completed
NCT01288911Phase 2Completed

Competing Products

20 competing products in Prostatic Neoplasms

See all competitors